Who
Gary A. Lyons
Director
Company insider
Files Form 4 as: Director, Travere Therapeutics; President and CEO, Neurocrine Biosciences; Director, Rigel Pharmaceuticals; Director, Eledon Pharmaceuticals; Director, Brickell Biotech; Director, Cerenome; Director, Kalobios Pharmaceuticals; Director, NeurogesX.
In numbers
- Trades disclosed
- 294
- Buys
- 5
- Sells
- 31
- Bought
- $32K
- Sold
- $26.0M
- Companies
- 11
- Companies where not an officer
- 10
- First trade
- 19 Jan 2006
- Last trade
- 18 Aug 2026
- Last filed
- 19 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Aug 2026filed 19 Aug 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 18 Aug 2026filed 19 Aug 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $87K5,000 at $17.44 | filing |
| 18 Aug 2026filed 19 Aug 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $259K4,100 at $63.27 | filing |
| 18 Aug 2026filed 19 Aug 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $57K900 at $63.86 | filing |
| 18 Aug 2026filed 19 Aug 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 18 Aug 2026filed 19 Aug 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $87K5,000 at $17.44 | filing |
| 18 Aug 2026filed 19 Aug 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $259K4,100 at $63.27 | filing |
| 18 Aug 2026filed 19 Aug 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $57K900 at $63.86 | filing |
| 17 Aug 2026filed 19 Aug 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $87K5,000 at $17.44 | filing |
| 17 Aug 2026filed 19 Aug 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $119K1,900 at $62.53 | filing |
| 17 Aug 2026filed 19 Aug 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $165K2,600 at $63.50 | filing |
| 17 Aug 2026filed 19 Aug 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $32K500 at $64.16 | filing |
| 17 Aug 2026filed 19 Aug 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 17 Aug 2026filed 19 Aug 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $87K5,000 at $17.44 | filing |
| 17 Aug 2026filed 19 Aug 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $119K1,900 at $62.53 | filing |
| 17 Aug 2026filed 19 Aug 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $165K2,600 at $63.50 | filing |
| 17 Aug 2026filed 19 Aug 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $32K500 at $64.16 | filing |
| 27 May 2026filed 29 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,284 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —2,624 at $0.00 | filing |
News
Travere (NASDAQ: TVTX) CEO sells 243,735 shares after option exercisesTVTX · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Gary A. Lyons; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.